

## Special Issue

# Molecular Mechanisms of Nerve Injury and Neuropathic Pain

### Message from the Guest Editors

Neuropathic pain is caused by lesions or diseases of the somatosensory system and is a major public health issue in the world. It is characterized by increased responses to nociceptive stimuli (hyperalgesia), unpleasant and abnormal sensations (dysesthesia), and pain in response to light tactile stimuli (allodynia). Studies show that neuropathic pain involves a series of pathophysiologic events when the nerve is damaged, including neuronal hyperexcitability, changes in perineuronal homeostasis, and neurogenic inflammation. Although the treatment for neuropathic pain remains a great challenge, progress has been made in identifying key molecules and their roles in pain modulation and processing. The purpose of this topic is to gather original research articles, reviews, and perspectives to advance our understanding of novel neuropathic pain-related molecules and signaling pathways that can be used as therapeutic targets for the treatment of pain.

### Guest Editors

Dr. Myeounghoon Cha

Department of Physiology, Yonsei University College of Medicine, Seoul 03722, Korea

Dr. Junesun Kim

Department of Physical Therapy, Korea University College of Health Science, Seoul 02841, Korea

### Deadline for manuscript submissions

closed (31 July 2022)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/104105](https://mdpi.com/si/104105)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).